← Product Code [JGS](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JGS) · K023049 # SYNCHRON LX I 725 CLINICAL SYSTEM (K023049) _Beckman Coulter, Inc. · JGS · Oct 4, 2002 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JGS/K023049 ## Device Facts - **Applicant:** Beckman Coulter, Inc. - **Product Code:** [JGS](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JGS.md) - **Decision Date:** Oct 4, 2002 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 862.1665 - **Device Class:** Class 2 - **Review Panel:** Clinical Chemistry ## Indications for Use The SYNCHRON LX®i 725 System combines the SYNCHRON LX®20 PRO analyzer and the Access® 2 analyzer into a single instrument presentation. Samples are loaded from a single point of entry through a Closed Tube Aliguotter (CTA) unit. The CTA functions as a sample processing manager by aliquotting and routing samples to the Access 2 and/or LX20 PRO analyzer according to programming requirements. The SYNCHRON LX20 PRO is a fully automated, computer-controlled clinical chemistry analyzer intended for the in vitro determination of a variety of general chemistries, therapeutic drugs, and other chemisiries of clinical interest in biological fluids such as serum, plasma, urine, or cerebrospinal fluid, (sample type is chemistry dependent). The Access 2 Immunoassay Analyzer is a microcomputer controlled, random access The analyzer performs enzyme immunoassays utilizing paramagnetic instrument. particle solid phase and chemiluminescent detection. The Access 2 Analyzer is intended for the in vitro determination of a variety of analytes of clinical interest in biological fluids such as serum, plasma, urine, and cerebral spinal fluid, (sample type is chemistry dependent). ## Device Story The SYNCHRON LXi 725 System is a clinical laboratory analyzer integrating the SYNCHRON LX20 PRO chemistry analyzer and Access 2 immunoassay analyzer. Samples are loaded via a single-point Closed Tube Aliquotter (CTA) module, which identifies, aliquots, and routes samples to the appropriate analytical module. The LX20 PRO performs photometric chemistry analysis; the Access 2 performs enzyme immunoassays using paramagnetic particle solid phase and chemiluminescent detection. A single LX20-based console serves as the user interface for programming, results management, and QC. The system features bar code identification, cap piercing, and obstruction detection. It is operated by laboratory personnel in a clinical setting. The integrated output allows clinicians to receive comprehensive chemistry and immunoassay results from a single sample, facilitating diagnostic decision-making. ## Clinical Evidence Bench testing only. Performance data from validation testing supports equivalency to the predicate system. ## Technological Characteristics Integrated clinical chemistry and immunoassay analyzer. Components: LX20 PRO analyzer, Access 2 module, CTA module. Sensing: Photometric detectors (chemistry), chemiluminescent detection (immunoassay). Sample handling: Closed Tube Sampling (CTS), cap piercing, bar code identification. Connectivity: Serial communications for remote control of Access 2 via LX20 console. Software: Version 3.0 operating software. ## Regulatory Identification A sodium test system is a device intended to measure sodium in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance. ## Predicate Devices - SYNCHRON LX®20 PRO System ([K011213](/device/K011213.md)) ## Reference Devices - Access 2 Immunoassay analyzer ([K922823](/device/K922823.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K023049 # 510(k) Summary SYNCHRON LX®i 725 System #### 1.0 Submitted By: Mary Beth Tang Requlatory Affairs Specialist Beckman Coulter, Inc. 200 S. Kraemer Blvd. W-104 Brea, CA 92822-8000 Telephone: (714) 961-3777 FAX: (714) 961-4123 #### 2.0 Date Submitted September 12, 2002 #### 3.0 Device Name(s): - 3.1 Proprietary Names: SYNCHRON LX®i 725 System - 3.2 Classification Names: Discrete photometric chemistry analyzer for clinical use [862.2160] #### 4.0 Legally Marketed Device The SYNCHRON LXi 725 System claims substantial equivalence to the SYNCHRON LX®20 PRO System currently in commercial distribution (Docket Number K011213). #### 5.0 Device Description The SYNCHRON LXi 725 System combines the SYNCHRON LX20 PRO analyzer and Access®2 Immunoassay analyzer into a single instrument presentation. Samples are loaded from a single point of entry through the Closed Tube Aliquoter (CTA) connector unit. The CTA functions as a sample processing manager by aliquotting and routing samples to the Access 2 and/or LX20 PRO modules according to programming requirements. The LX20 PRO and Access 2 systems then deliver samples to the appropriate reaction vessel along with reagents and reaction constituents. The LX20based console functions as the single user interface for managing routine operations such as sample programming, results management, and QC functions. The LXi system provides analysis of up to 65 analytes per sample, operating in conjunction with the existing reagents, calibrators, and controls designed for use with the LX20 PRO and Access 2 analyzers. The instrument features bar code identification of samples and reagents, Closed Tube Sampling (CTS), and obstruction detection and correction capability. LXi system components include the LX20 PRO analyzer and console, the CTA module, and the Access 2 module and console. The subsystem hardware components for the analytical units include reagent storage compartments, sample and reagent delivery systems, cap piercing assemblies, sample carousels and cranes, hydropneumatics, fluidics, photometric detectors, electronics, and power supplies. {1}------------------------------------------------ The LXi configuration incorporates the following upgrades to the LX20 PRO System: #### Closed Tube Aliquotter (CTA) Module 1. The CTA serves as the connector between the Access 2 and LX20 PRO systems. The CTA module performs sample identification, aliquot preparation, and sample routing to programming requirements. The CTA uses disposable aliquot vessels for Access 2 sampling. The key hardware components include a laser bar code reader, sample rack shuttle, cap piercer, aliquot probe, sample wheel, wash station, and gantry. #### 2. Access 2 Immunochemistry Module (previously reviewed/cleared under K922823) The Access 2 analyzer expands the chemistry menu of the LX20 PRO System. An additional serial communications line allows remote control of the Access 2 instrument through the LX20-based console. # 3. Hardware Modifications The LX20 PRO sample rack shuttle and instrument covers have been modified to accommodate the CTA and Access 2 modules and to visually integrate the system. #### Software Modifications ধ, The LXi System utilizes LX20 operating software version 3.0. Version 3.0 contains the information necessary to configure, order, and report results for Access 2 tests. #### 6.0 Intended Use The SYNCHRON LX®i 725 System combines the SYNCHRON LX®20 PRO analyzer and the Access®2 analyzer into a single instrument presentation. Samples are loaded from a single point of entry through a Closed Tube Aliguotter (CTA) unit. The CTA functions as a sample processing manager by aliquotting and routing samples to the Access 2 and/or LX20 PRO analyzer according to programming requirements. The SYNCHRON LX20 PRO is a fully automated, computer-controlled clinical chemistry analyzer intended for the in vitro determination of a variety of general chemistries, therapeutic drugs, and other chemistries of clinical interest in biological fluids such as serum, plasma, urine, or cerebrospinal fluid. (sample type is chemistry dependent). The Access 2 Immunoassay Analyzer is a microcomputer controlled, random access instrument. The analyzer performs enzyme immunoassays utilizing paramagnetic particle solid phase and chemiluminescent detection. The Access 2 Analyzer is intended for the in vitro determination of a variety of analytes of clinical interest in biological fluids such as serum, plasma, urine, and cerebral spinal fluid, (sample type is chemistry dependent). #### 7.0 Comparison to the Predicate The SYNCHRON LX20 PRO system has been upgraded to an LXi system through 1) modifications to the sample rack shuttle and instrument covers. 2) the addition of a preanalytical CTA unit and an Access 2 Immunoassay analyzer, and, 3) a software update to version 3.0. There is also a name change to LXi 725 System. #### 8.0 Summary of Performance Data Performance data from validation testing supports equivalency. {2}------------------------------------------------ # Section 1: ADMINISTRATIVE INFORMATION ## 1.0 Submitted By: Beckman Coulter, Inc. 200 S. Kraemer Blvd. W-104 Brea, CA 92822-8000 Primary Contact: Mary Beth Tang, Regulatory Affairs Specialist Telephone: (714) 961-3777 FAX: (714) 961-4123 E-mail: mtanq@beckman.com Secondary Contact: Annette Hellie, Requlatory Affairs Manager Telephone: (714) 993-8767 FAX: (714) 961-4123 # 2.0 Sponsor Address/FDA Registration Number Beckman Coulter, Inc. 200 S. Kraemer Blvd. W-104 Brea, CA 92822-8000 Establishment Registration No. 2050012 # 3.0 Product Name/Classification Name and Number Proprietary Names SYNCHRON LX®i 725 System Classification Names Discrete photometric chemistry analyzer for clinical use [862.2160] # 4.0 Device Classification FDA has classified clinical chemistry test systems of this type into Class I (reserved) ### 5.0 Section 514 Compliance This Special 510(k): Device Modification submission is prepared pursuant to the FDA publication: The New 510(k) Paradigm: Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications -Issue Date: March 20, 1998. {3}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus symbol. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Ms. Mary Beth Tang Regulatory Affairs Specialist Beckman Coulter, Inc. 200 S. Kraemer Blvd. M/S W-104 Box 8000 Brea, CA 92822-8000 OCT 0 4 2002 Re: k023049 Trade/Device Name: SYNCHRONLX®I 725 System Regulation Number: 21 CFR 862.1665 Regulation Name: Sodium test system Regulatory Class: Class II Product Code: JGS; CHH, CDZ, CEO, DIH, JHB, JIF, JIY, JMO, CDD, CDP, CDQ, CEC, CEE, CEK, CEM, CFJ, CFR, CGA, CGR, CGS, CGX, CGZ, CIN, CJE, CJW, CZP, DCF, DCK, DDC, DDG, DDG, DDR, DFT, DGC, DHR, DIO. DIS, DJG, DJR, DKJ, DKZ, DLZ, DMT, GTQ, JFJ, JFL, JFM, JFP, JGS, JHI, JHW, JHX, JLW, JMG, JXM, KLI, KLS, KLT, KXS, KXT, LCD, LCM, LCP, LCR, LDJ, LDP, LEG, DHX, LFX, LGD, LJC, MRR, MSJ, MSW Dated: September 12, 2002 Received: September 13, 2002 Dear Ms. Tang: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {4}------------------------------------------------ Page 2. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours. Steven Sutman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ page 1 of 1 510(k) Number (if known): Device Name: Indications for Use: The SYNCHRON LX®i 725 System combines the SYNCHRON LX®20 PRO analyzer and the Access® 2 analyzer into a single instrument presentation. Samples are loaded from a single point of entry through a Closed Tube Aliguotter (CTA) unit. The CTA functions as a sample processing manager by aliquotting and routing samples to the Access 2 and/or LX20 PRO analyzer according to programming requirements. The SYNCHRON LX20 PRO is a fully automated, computer-controlled clinical chemistry analyzer intended for the in vitro determination of a variety of general chemistries, therapeutic drugs, and other chemisiries of clinical interest in biological fluids such as serum, plasma, urine, or cerebrospinal fluid, (sample type is chemistry dependent). The Access 2 Immunoassay Analyzer is a microcomputer controlled, random access The analyzer performs enzyme immunoassays utilizing paramagnetic instrument. particle solid phase and chemiluminescent detection. The Access 2 Analyzer is intended for the in vitro determination of a variety of analytes of clinical interest in biological fluids such as serum, plasma, urine, and cerebral spinal fluid, (sample type is chemistry dependent). Sean Cooper (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number K023049 (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (per 21 CFR 801.109) OR Over-the-Counter Use Optional Format 1-2-96 --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JGS/K023049](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JGS/K023049) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com